Apoptotic cell-based therapies against transplant rejection: role of recipient's dendritic cells

Apoptosis. 2010 Sep;15(9):1083-97. doi: 10.1007/s10495-010-0469-9.

Abstract

One of the ultimate goals in transplantation is to develop novel therapeutic methods for induction of donor-specific tolerance to reduce the side effects caused by the generalized immunosuppression associated to the currently used pharmacologic regimens. Interaction or phagocytosis of cells in early apoptosis exerts potent anti-inflammatory and immunosuppressive effects on antigen (Ag)-presenting cells (APC) like dendritic cells (DC) and macrophages. This observation led to the idea that apoptotic cell-based therapies could be employed to deliver donor-Ag in combination with regulatory signals to recipient's APC as therapeutic approach to restrain the anti-donor response. This review describes the multiple mechanisms by which apoptotic cells down-modulate the immuno-stimulatory and pro-inflammatory functions of DC and macrophages, and the role of the interaction between apoptotic cells and APC in self-tolerance and in apoptotic cell-based therapies to prevent/treat allograft rejection and graft-versus-host disease in murine experimental systems and in humans. It also explores the role that in vivo-generated apoptotic cells could have in the beneficial effects of extracorporeal photopheresis, donor-specific transfusion, and tolerogenic DC-based therapies in transplantation.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Apoptosis*
  • Cell Transplantation*
  • Cell- and Tissue-Based Therapy
  • Dendritic Cells / immunology*
  • Graft Rejection* / immunology
  • Graft vs Host Disease / immunology*
  • Graft vs Host Disease / physiopathology
  • Humans
  • Immunosuppression Therapy*
  • Mice